Innovating to Impact: Dentsu Unveils New Global Brand Proposition Drawing Upon 120 Year Heritage

Dentsu, Innovating to Impact
Dentsu, Innovating to Impact

TOKYO, May 16, 2024 (GLOBE NEWSWIRE) — Dentsu, today announced the launch of its new global, client-facing, brand proposition, “Innovating to Impact”, marking a significant milestone in the company’s storied 120-year plus history. The new go-to-market brand encapsulates dentsu’s commitment to driving growth through innovation, leveraging the collective strengths of transformative creativity, media, data, and technology.

Created through a collaborative effort of many dentsu teams around the world, “Innovating to Impact” reflects dentsu’s dedication to delivering outcomes that not only drive business growth but also generate a positive effect on people, society and the world.

“Our new branding is a bold declaration of our unwavering commitment to innovate in pursuit of outcomes on behalf of our clients,” said Hiroshi Igarashi, President & Global CEO, dentsu. “At dentsu, we are not content with simply following trends; we aim to set them. ‘Innovating to Impact’ is our promise to our clients, our incredible people and the communities we serve, that we will continue to push the boundaries of what’s possible through experience and business transformation.”

The launch is the next stage in dentsu’s mid to long-term strategy and its positioning as an integrated growth and transformation partner to the world’s leading organizations. Dentsu brings the best of both worlds to clients: individual global leadership brands that can deliver deep expertise, and the ability to tie those services together to deliver a multiplier effect for clients as dentsu.

A Dentsu Creative team, headed by Riccardo Fregoso, Chief Creative Officer Dentsu Creative Italy, led development of the tagline “Innovating to Impact”, along with a new brand manifesto. The design look and feel of the new brand was produced by the multi-award winning Dentsu Inc. team in dentsu Japan, led by Executive Creative Director, Yoshihiro Yagi, one of Japan’s most internationally awarded, art-based creatives.

“For over 120 years, innovation has been a core tenet of dentsu’s offering; it is in our DNA and within the very culture of our teams around the world. Innovation for dentsu is both an open mindset as well as a systematic approach, helping clients approach their business transformation in new ways,” commented Jean Lin, Global President – Global Practices, dentsu. “Dentsu is truly unique in the market, sitting at the convergence of marketing, technology and consulting. When we combine innovation with a laser focus on driving outcomes, we bring together the best of our capabilities to deliver integrated growth for brands who want something different from the traditional model.”

Dentsu’s new brand will be further showcased at the Cannes Lions Festival in June 2024, with dentsu Beach House programming and design reflecting the principles and positioning of “Innovating to Impact”.

For more information about dentsu and the new GTM brand, please visit: Innovating to Impact

Team credits:

Dentsu Creative Italy

Riccardo Fregoso, Chief Creative Officer
Stefano Battistelli, Executive Creative Director
Francesco Epifani, Executive Creative Director
Cristiana Bregni, Art Director
Santiago Cancela, Copywriter

Dentsu Inc., Japan

Yoshihiro Yagi, Executive Creative Director
Tsubasa Adachi, Creative Director
Haruko Tsutsui, Creative Director
Hiroyuki Kato, Art Director
Natsuki Tomoda, Art Director
Miyuki Ito, Copywriter
Mariko Fukuoka, Copywriter
Shintaro Murakami, Digital Technologist

About dentsu

Dentsu is an integrated growth and transformation partner to the world’s leading organizations. Founded in 1901 in Tokyo, Japan, and now present in over 145 countries and regions, it has a proven track record of nurturing and developing innovations, combining the talents of its global network of leadership brands to develop impactful and integrated growth solutions for clients. Dentsu delivers end-to-end experience transformation (EX) by integrating its services across Media, CXM and Creative, while its business transformation (BX) mindset pushes the boundaries of transformation and sustainable growth for brands, people and society.

Dentsu, Innovating to Impact.

Find out more:

www.dentsu.com
www.group.dentsu.com

Contact:

Matt Cross
Email: matt.cross@dentsu.com

A photo accompanying this announcement is available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/0b229c64-e587-4c92-80d2-8fb28b25ff1f

GlobeNewswire Distribution ID 1000951315

Tealium unveils CDP integration with Snowflake’s Snowpipe Streaming API

The integration combines the powerful forces of the Snowflake Data Cloud and Tealium CDP to accelerate CX across the entire customer journey

San Diego, May 16, 2024 (GLOBE NEWSWIRE) — Tealium announced today that it is one of the first customer data platforms (CDPs) to seamlessly connect to Snowflake’s Snowpipe Streaming API, offering industry-leading customer data collection and activation capabilities. Tealium’s CDP, powered by Snowflake, streamlines the process of landing low latency customer behavior data into the Snowflake Data Cloud to power analytics, AI, and customer-360 initiatives, allowing enterprises to better serve and engage their customers.

“At the heart of any CX strategy, is your data. CDPs and cloud data platforms are powerful catalysts for managing, analyzing, and activating customer data successfully to achieve this. And although unique on their own, together, they become a powerful force. That’s why Tealium and Snowflake are truly better together, providing a centralized consented data hub combining the benefits of historical data, real-time behavior, and utmost flexibility,” says Bob Page, Chief Product Officer at Tealium.

Real-time access to customer data is crucial for organizations to stay competitive and deliver exceptional customer experiences. Tealium’s integration with the Snowpipe Streaming API enables businesses to capture, process, analyze, and activate data efficiently. This powerful combination allows organizations to unlock valuable insights, enhance personalization, and make data-driven decisions, ultimately driving growth and customer satisfaction.

The integration leverages the power of a real-time CDP coupled with Snowflake’s elastic performance engine to drive customer data capabilities, including:

  • Establish unified and actionable customer views to power real-time engagement, leveraging enhanced identity data in Snowflake
  • Fuel and activate AI initiatives across the entire data infrastructure 
  • Minimize wasted time on data wrangling for more strategic and higher-quality insights 
  • Reduce regulatory risk by enabling consented data collection and activation, honoring customer privacy preferences across the entire journey
  • Improve ROI and achieve business goals through enhanced measurement and data-driven decision making

“As third-party cookies phase out and privacy regulations intensify, the demand for secure, privacy-first, real-time data solutions has never been greater,” said Onil Gunawardana, Head of Product Management, Marketing Data Cloud, at Snowflake. “Tealium’s advanced CDP with consent management, integrated with Snowflake’s Snowpipe API, provides enterprises with immediate access to cleansed, high-quality, first-party data. This seamless connectivity not only speeds up data ingestion for AI and improves customer experiences, but also ensures that data usage remains compliant within Snowflake’s robust analytics environment, elevating customer data strategies with unmatched security and efficiency.”

The integration also equips teams with widened flexibility, allowing them to augment customer data with AI, fueling models with clean and consented data. With every business having an AI mandate, the biggest challenge being faced during initial adoption is access to AI-ready data. The Tealium and Snowflake integration enforces enhanced data quality and governance, which supports successful AI implementation across the enterprise.

Learn more about how Tealium and Snowflake are better together.

To keep up with the latest company news, visit Tealium’s Newsroom.

Join the Real-Time Revolution: Tealium is hosting its annual Digital Velocity conference in San Diego on June 10-12, 2024. Join industry leaders as they come together to discuss the latest innovations in customer data. On Tuesday, June 11, Patrick Crosby, Senior Alliance Manager for Technology Partners at Snowflake, will be speaking in a session on “Driving Growth through Data Integration: CDPs and the Snowflake Marketing Data Cloud in Concert.”  Learn more and register here. 

 

About Tealium 

As the most trusted CDP, Tealium connects data so businesses can better connect with their customers. Tealium’s real-time data infrastructure allows brands to power their AI models and activate data for enhanced in-the-moment experiences. Tealium’s turnkey integration ecosystem supports more than 1,300 built-in connections from the world’s most prominent technology experts. Tealium’s solutions include a real-time customer data platform with machine learning, tag management, an API hub, and data management solutions that make customer data more valuable, actionable, privacy-compliant, and secure. Named as a Leader in the Gartner® Magic Quadrant for Customer Data Platforms™, more than 850 leading businesses globally trust Tealium to power their customer data strategies. For more information, visit www.tealium.com.

Natalie Passarelli
Tealium Inc. 
3129650210
natalie.passarelli@tealium.com

GlobeNewswire Distribution ID 9118839

Braving the extreme: Deriv-sponsored Patagonian expedition Kahuna and its impact on climate science

Collecting snow samples for research

Two explorers collecting snow samples as part of the Kahuna expedition.

Two explorers collecting snow samples – Deriv Kahuna
  • Deriv’s CSR sponsorship programme supports the Kahuna team in collecting essential environmental data and improving global understanding of climate change.
  • In partnership with OSER and Cheer Up, the environmental expedition aims to uplift and educate young patients and students.

CYBERJAYA, Malaysia, May 16, 2024 (GLOBE NEWSWIRE) — As Deriv gears up to celebrate 25 years of innovation and responsibility, it proudly marks this milestone through a series of new initiatives that will have an impact in 2024 and beyond. The Kahuna sponsorship supports scientific research and community projects that provide educational value and inspire positive action towards protecting the environment.

Deriv recently sponsored the Kahuna team to carry out an environmental research expedition in Patagonia. The environmental expedition aimed to investigate the presence of microplastics and black carbon in the snow. These substances are critical indicators of environmental pollution that affect climate change.

The team partnered with the Argentinian Institute of Nivology, Glaciology, and Environmental Sciences and sought community outreach through collaborations with charitable organisations OSER and CheerUp (affiliated with CentraleSupelec).

The Kahuna team hiking with their heavy backpacks

Hikers with their backpacks – Deriv Kahuna

Seema Hallon, Chief Human Resources Officer of Deriv, shares, “The 25th anniversary is an opportunity for Deriv to recommit to the things that matter to us as an organisation. Investing our CSR efforts in meaningful projects such as the Kahuna expedition is our way of contributing to the efforts for a sustainable future for the planet and communities.”

The expedition began in mid-January in Puerto Murta, Chile, with a team consisting of Baptistin Coutance, Robin Villard, Thomas Jarrey, Vincent Lavrov, and Yvan Lazard.

The route took them across Lago General Carrera, through Rio Baker into the Pacific fjords, along the Campo De Hielo Continental, ascending Volcan Lautaro and Cerro Francisco Moreno, where bad weather conditions led to an early ending of the journey.

Robin Villard shares, “The expedition was a success. The samples collected are in good condition and are scheduled for analysis in May and July. By the end of the summer, we should have results on the presence of microplastics in the ice field below. That’s a huge success.

“Our scientific research aimed to collect snow samples for analysis to determine the level of microplastics. Simply put, the samples will be examined under a microscope in the lab to see if there is significant pollution from microplastics in the snow.”

Expedition outcomes:

  • Research impact: The Kahuna team successfully collected and analysed samples from the region, providing valuable data for ongoing climate studies.
  • Community impact: Through real-time updates and subsequent presentations, the environmental expedition will provide educational and motivational experiences to young cancer patients and underprivileged students once their documentary film is ready.

The expedition faced challenges — adverse weather conditions and dangerous terrain, but could complete their research objectives effectively.

Hikers with their Deriv-branded backpacks

Read more about the Kahuna expedition.

About Deriv

For 25 years, Deriv has been committed to making online trading accessible to anyone, anywhere. Trusted by over 2.5 million traders worldwide, the company offers an expansive range of trade types and boasts over 200 assets across popular markets on its award-winning, intuitive trading platforms. With a workforce of more than 1,400 people globally, Deriv has cultivated an environment that celebrates achievements, encourages professional growth, and fosters talent development, which is reflected in its Platinum accreditation by Investors in People.

PRESS CONTACT
pr@deriv.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/ef2965d5-c8b1-4871-bacc-0269b2f6db03
https://www.globenewswire.com/NewsRoom/AttachmentNg/566a2521-6397-441c-9785-dde4576f6cb7

GlobeNewswire Distribution ID 9118271

Workvivo by Zoom is named preferred migration partner for Workplace from Meta

Meta is discontinuing Workplace and will partner with Workvivo to assist with customer transitions.

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Today, Workvivo by Zoom was named Meta’s only preferred migration partner for its customers as it retires Workplace from Meta.

Meta is discontinuing Workplace from Meta – its employee engagement platform. To assist with customer transitions, Meta will partner with Workvivo as its only preferred migration partner.

Workplace from Meta and Workvivo plan to provide migration tools for customers migrating to Workvivo and Workvivo will also offer additional implementation services at no further cost to support customers’ transition.

Workplace from Meta customers can find more information about migrating to Workvivo here.

John Goulding, CEO and founder of Workvivo, said: “We know that the news today may be disruptive for Workplace from Meta customers, but we’re so excited about the opportunity to support and help them. Meta has made a huge impact in this market, and we believe that Workvivo is the natural choice for Workplace from Meta customers to transition their employee experience platform.

“It’s our top priority to support customers through this transition, and our team is working to make this process as frictionless as possible. We put our customers first, and this will be no different for the Workplace from Meta customers. We are excited to welcome Workplace from Meta customers into our incredible customer community and see the amazing things they can do with Workvivo.”

Eric S. Yuan, CEO and founder of Zoom said: “Since Workvivo joined the Zoom family, we’ve seen how powerful this platform is at engaging workforces and bringing culture to life – especially for frontline employees who may not have a desk or even an email address. Workvivo has seen momentous growth as organizations around the world are increasingly prioritizing the employee experience. We are excited to support Workplace from Meta’s customers and help them reach their goals of reaching and engaging employees – whether they’re desk or frontline workers.”

Workvivo by Zoom is the employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work.

Acquired by Zoom in 2023, Workvivo extends the Zoom Workplace platform to offer its customers new ways to keep employees informed, engaged, and connected. Workvivo is working with some of the world’s best-known brands to help them boost employee engagement and bring their culture to life digitally, including Dollar General, the Virgin Group, Bupa, Ryanair, Lululemon and Amazon.

About Workvivo by Zoom

Workvivo is an employee experience platform that simplifies communication and increases engagement by empowering employees to be heard and helping everyone feel included, no matter where they work. The platform unifies employee communications, engagement, intranet, and measurement features into one modern employee app that captures the heartbeat of the organization and brings its culture to life.

Founded in 2017, Workvivo has seen momentous growth, which led to its acquisition by Zoom in 2023. Workvivo powers the employee experience at companies all over the world across all industries, including Amazon, Motherson, White Castle, Bupa and Ryanair. Workvivo regularly tops software review sites, including Gartner Digital, with a #1 spot on G2 for internal communications, intranet and engagement tool categories. For more information, visit www.workvivo.com.

Public Relations
Eleanor O’Mahony
eleanor.omahony@zoom.us

GlobeNewswire Distribution ID 9117415

MedSource Labs Announces Innovation in Safety, Accuracy and Functionality of IV Catheters

MedSource Labs Unveils ClearSafe Comfort® and TrueSafe Comfort® Blood Control Safety IV Catheters to protect medical staff and patients

[Minneapolis, Minnesota, Chanhassen], May 14, 2024 (GLOBE NEWSWIRE) — MedSource Labs moves the needle in the peripheral safety IV market with the announcement of ClearSafe Comfort and TrueSafe Comfort Blood Control IV Catheters with groundbreaking active blood control check valve technology.

ClearSafe Comfort and TrueSafe Comfort Blood Control IV catheters provide significant benefits over other IV catheters.

  1. Safety: A new blood control device to significantly reduce the risk of exposure to bloodborne pathogens to the caregiver and patient.
  2. Precision: A translucent flashback chamber confirms vessel entry and ensures accuracy.
  3. Front-line functionality: The ergonomic design and non-slip grip ensure easy handling for healthcare workers.

 

“Healthcare professionals subject themselves to the risks associated with needlestick injuries and exposure to bloodborne pathogens every time they access a vein,” said Dave Kunelius, President at MedSource Labs. “ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters have been engineered to minimize these risks, allowing medical staff to better serve their patients without distraction or worry.”

These devices conform to the U.S. Needlestick Safety and Prevention Act.

MedSource Labs is a leading medical product developer and supplier specializing in high-quality products and innovative medical product development. The ClearSafe Comfort and TrueSafe Comfort Blood Control Safety IV Catheters are part of MedSource Labs’ high-performing IV catheter lines focused on caring for the caregiver. See the TrueSafe Animations and ClearSafe Animations for a detailed view.

“Quality has always been a key component of our IV catheter products, and the ClearSafe Comfort and TrueSafe Comfort blood control products raise the bar for medical staff safety and patient care,” said Kunelius.

MedSource Labs is ISO 13485:2016 certified for quality management in medical device manufacturing, registered with the FDA, and the blood control catheters are 510(k) Cleared Products.

ABOUT MEDSOURCE LABS

MedSource Labs is a leading provider of quality medical products, specializing in high-quality products, equipment and innovative class II medical product development. For over two decades, MedSource Labs has been a trusted provider of quality medical products at a superb value. Recently, MedSource Labs has expanded into new markets and grown its international services and offerings, including a focus on the EMERGE product imagine/design/build process.

Attachment

Jeremy Belloit
MedSource Labs
(952) 472-0131
jbelloit@medsourcelabs.com

GlobeNewswire Distribution ID 9116905

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations
King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

RIYADH, Saudi Arabia, May 13, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) has recently welcomed Dr. Björn Zoéga as its Deputy CEO, an appointment that underscores its commitment to promoting and fostering healthcare excellence. Dr. Zoéga, renowned for his extensive experience in healthcare management and policy, joins a dedicated team as the hospital continues to drive key strategic initiatives.

KFSH&RC, a leader in medical research and clinical services, continues to attract global expertise to bolster its vision of healthcare excellence. With Dr. Zoéga’s involvement, the hospital is advancing a digital transformation strategy designed to improve operational efficiency and enhance patient care. His expertise in fostering international collaborations, evidenced by his former role as president of the European University Hospital Alliance (EUHA) and through initiatives like JOIN4ATMP aimed at advancing access to innovative therapies, further aligns KFSH&RC’s services with global healthcare trends.

Key projects at KFSH&RC include the deployment of advanced digital technologies to streamline the patient care process, the adoption of innovative care models, and the upgrading of facility amenities. These strategic efforts aim to improve access to medical services and facilitate better communication, reflecting KFSH&RC’s dedication to setting new standards in healthcare.

Dr. Zoéga’s previous contributions at Karolinska University Hospital, which is ranked the second best in Europe and seventh globally by Newsweek’s 2024 World’s Best Hospitals, where he nurtured a culture of continuous learning and collaboration among healthcare professionals, align well with KFSH&RC’s objectives. His role in fostering programs like EUCARE and facilitating the Europe-wide exchange of intensive care nurses during crises has significantly enhanced staff development and supported his previous hospital’s goal of attracting top talent—a principle mirrored in KFSH&RC’s transformation journey. With Dr. Zoéga contributing to leadership, KFSH&RC is poised to further its role as a pivotal player in shaping the future of healthcare in Saudi Arabia.

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605-9a75-41cb-8947-81c858209621

GlobeNewswire Distribution ID 9116335

Impulse Dynamics Surpasses 10,000 Patients Benefiting From CCM® Therapy for Heart Failure

Milestone Highlights Transformative Symptom Management for Patients Living with Heart Failure

Marlton, NJ, May 13, 2024 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today that it has reached a worldwide milestone by surpassing 10,000 patients having received the Optimizer® system for the treatment of moderate HF. This milestone highlights the benefit and importance of this therapy in helping patients live a full life with HF.

“I noticed positive changes since the procedure, such as not feeling cold or numb, I could walk every day and everywhere, did my regular chores and shopping, and shared activities like swimming with my daughter,” said Tracey, who received her CCM® device in 2023. “I’m no longer huffing, puffing, or gasping for air,” said Joe, another HF patient who received his CCM device in 2022. “I’m reborn ─ a whole new person ─ no longer incapacitated. My life has changed so much that we’re considering taking a trip. And my wife is ecstatic because I have my life back, and we have ours again.”

“We are deeply motivated by the patients who benefit from CCM therapy. Their progress inspires us to continuously enhance our technology, aiming to improve the lives of those suffering from heart failure,” said David Prutchi, Chief Technology Officer for Impulse Dynamics, who has worked on the development of CCM therapy since its inception.

David had the opportunity to meet one of these patients, Raynita, who was implanted with an Optimizer device this year. Raynita saw immediate improvement after starting CCM therapy and gave the following remarks on the experience: “I feel like a different person. I can do things I haven’t done in years. I am attending my granddaughter’s college graduation!”

CCM is available in 44 countries, and the technology has continued to advance, based on the needs of patients and physicians. The latest generation of the proprietary CCM technology is the Optimizer Smart Mini, which offers a rechargeable battery with 20-year battery life and a smaller size designed to make the implant procedure faster and easier for patients and physicians.

“We are committed to ongoing innovation in this important therapy that has such a clear clinical need around the world,” said Jason Spees, CEO of Impulse Dynamics. “We are also getting closer to significantly impacting the implantable cardioverter defibrillator (ICD) market with successful enrollment in our INTEGRA-D clinical trial on the CCM-D® HF System, which is the first-of-its-kind technology, combining the lifesaving benefits of an ICD with HF symptom relief through CCM therapy in one device.”

The patients statements in this Press Release represent the testimonials of their individual outcomes and may not be typical for all patients.

About the Optimizer and CCM Therapy 

The Optimizer Smart Mini system delivers CCM therapy — the company’s proprietary technology — to the heart, providing an important treatment option for the millions of patients suffering from heart failure. CCM therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body.[1] CCM therapy is indicated to improve 6-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not indicated for CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent.

CCM is the brand name for cardiac contractility modulation—the non-excitatory electrical pulses delivered by the implantable Optimizer device to improve heart contraction. CCM therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM helps the heart contract more forcibly. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, the results of which appeared in more than 100 articles from leading medical journals.

About Impulse Dynamics

Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in HF patients. CCM therapy is delivered through the Optimizer system, which includes an implantable pulse generator (IPG) implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 10,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, X (formerly Twitter), and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.


[1] European Journal of Heart Failure (2021) doi:10.1002/ejhf.2202

Attachment

Scott Way, Executive Vice President, General Counsel
Impulse Dynamics
856-434-7906
sway@impulsedynamics.com

Rohan More, Global Vice President, Marketing
Impulse Dynamics
856-642-9933
rmore@impulsedynamics.com

GlobeNewswire Distribution ID 9116301

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

RIYADH, Saudi Arabia, May 11, 2024 (GLOBE NEWSWIRE) — Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at Harvard University. In his address, Dr. Al Fayyadh showcased the KFSH&RC’s journey since its inception in Riyadh almost five decades ago, highlighting how it has significantly reduced the need for patients to travel abroad for medical care. KFSH&RC has evolved into a premier provider of tertiary healthcare services and today offers cutting-edge treatments for heart diseases, tumors, organ transplantation, and genetic disorders.

Dr. Al Fayyadh discussed KFSH&RC’s transformation into an independent, non-profit foundation. This move, he indicated, aligns with the organization’s strategic vision to become a global healthcare innovation leader, emphasizing excellence, innovation, and investment in cutting-edge technology to tackle global health challenges.

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

“The Saudi Leadership has outlined a clear vision for KFSH&RC, mandated by a royal decree transitioning the hospital into an independent Sui Generis, non-profit foundation,” stated His Excellency, Dr. Al Fayyadh.

He further highlighted that this transformation seeks to elevate global healthcare standards through increased independence and flexibility. This shift will allow KSFH&RC to optimize existing services, pursue new opportunities, and direct resources toward initiatives that promote human health and well-being both within the Kingdom and internationally. Ultimately, this move reinforces KFSH&RC’s dedication to patient-centered excellence.

Dr. Al Fayyadh pointed out that KFSH&RC envisions itself as a leader in maximizing the value of healthcare spending, adhering to evidence-based practices to ensure optimal patient outcomes. It seeks to remain at the forefront of global healthcare innovation, with initiatives designed to increase health equity and access worldwide. To achieve this, KFSH&RC will continue to invest in cutting-edge medical facilities, advanced diagnostic equipment, and state-of-the-art treatment technologies. Building on existing progress in areas like CAR T-cell therapy, robotic surgeries, organ transplants, and personalized medicine, the institution aims to achieve global competitiveness. This will be further supported by fostering an exceptional workforce, pursuing Nobel Prize-caliber breakthroughs, and strengthening strategic international collaborations.

KFSH&RC CEO at GCC Harvard 2

Dr. Al Fayyadh joined a panel discussion focusing on the evolving landscape of the healthcare sector and the positive outcomes of KFSH&RC’s ongoing transformation in patient care. He also addressed current challenges and anticipated future developments within the healthcare sector, emphasizing the profound impact of the hospital’s innovations on global healthcare advancement. Additionally, Dr. Al Fayyadh highlighted the effective role of the hospital’s transformative initiatives in aligning with the objectives of the Health Sector Transformation Program and Saudi Vision 2030.

KFSH&RC is recognized as one of the leading global institutions that provide specialized healthcare, drive innovation, and serve as an advanced medical research and education hub. It is dedicated to developing medical technologies and elevating healthcare standards worldwide, forging partnerships with leading local, regional, and international institutions to deliver world-class services in clinical, research, and educational domains.

For the second year running, KFSH&RC has retained its status as the leading institution in the Kingdom and ranks 20th globally among the top 250 academic medical centers worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance, and has been ranked among the world’s top 250 hospitals by Newsweek Magazine.

KFSH&RC CEO at GCC Harvard 1

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27-fa87-49ac-b72b-ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee-20a5-4328-bf00-e036bc3350fd

GlobeNewswire Distribution ID 9115814

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

RIYADH, Saudi Arabia, May 10, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence—Oncology, Genomics, and Transplantation.

KFSH&RC’s Oncology Centre of Excellence continues to lead the fight against the disease in the Kingdom. This year alone, the centre has treated 25% of all cancer cases in Saudi Arabia, achieving a 50% overall recovery rate and up to 90% recovery in leukemia cases. With almost five decades of service, the centre’s commitment to providing advanced cancer treatments is evident in its adoption of technologies such as CAR T-cell therapy and liquid biopsy, which provide less invasive alternatives to traditional methods, along with extensive bone marrow transplants, and revolutionary techniques like Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

Notably, KFSH&RC has achieved a milestone by completing over 100 CAR T-cell therapy procedures, a novel treatment that genetically modifies a patient’s immune cells to fight cancer. This achievement puts it on par with renowned institutions that are also advancing CAR-T cell therapy for various blood cancers and exploring expanded applications through clinical trials and new treatment protocols. Furthermore, the centre’s focus on pediatric oncology boasts a 97% five-year survival rate for renal tumors and a 92% survival rate for acute lymphoblastic leukemia in children.

With rapid advancements in genomic medicine, KFSH&RC is adopting next-generation sequencing technologies into patient care in its Genomic Centre, revolutionizing local and regional approaches to disease management. KFSH&RC’s discovery of the bacterial strain Stenotrophomonas Riyadhensis, facilitated by whole-genome sequencing (WGS) technology, has contributed to our understanding of bacterial antibiotic resistance mechanisms. With 15,698 patient visits and over 5,658 whole genomes completed in 2023, the centre ensures that prevention, diagnosis, and treatment are precise and personalized.

KFSH&RC’s Organ Transplant Centre of Excellence (OTCoE) continues to be the primary contributor to organ transplantation activities in the Kingdom, accounting for 65% of all transplants performed nationally. In 2023, OTCoE performed 1,092 solid organ transplants, including the world’s first fully robotic liver transplant— where doctors employed robotic technology to conduct surgery on both patient and donor — an achievement that places the centre at the forefront of global transplantation practices.

As KFSH&RC continues to push the boundaries of what is possible in medical science, its efforts not only inspire but also significantly impact the global healthcare community, reaffirming its role as a leader in medical innovation and specialized healthcare.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Acting Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee

GlobeNewswire Distribution ID 9115490

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) — Harvard University — Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care. Strategic investments in infrastructure, technology, and talent, have led to advancements revolutionizing patient care delivery and elevating the standards of healthcare locally. These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom.

Central to these achievements, King Faisal Specialist Hospital & Research Centre (KFSH&RC), renowned for its specialized care and treatments across critical fields such as oncology, cardiology, organ transplantation, and genetics has positioned itself as a leader in specialized patient care, taking the charge towards a brighter, healthier future for the Kingdom. Through its commitment to pioneering digital health initiatives, comprehensive educational programs, and novel research endeavors, it is reshaping the local landscape, and setting new standards of efficiency and accessibility.

In an era defined by technological advancements, and with the Kingdom’s push towards digitalization, KFSH&RC stands at the forefront of digital health integration among its local peers, leveraging cutting-edge telemedicine services, virtual consultations, and AI-driven tools such as the ANFAL AI System that transforms patient outcomes through predictive insights and personalized care, ensuring the best outcomes for patient satisfaction.

KFSH&RC’s digital health initiatives extend to addressing broader health threats through technologies such as Whole Genomic Sequencing (WGS) and Advanced Radiation Therapy. The hospital has also pioneered organ transplantation by performing the world’s first fully robotic liver transplant and introduced to the region innovations like the Harmony Transcatheter Pulmonary Valve (TPV), enhancing patient recovery and experience. These technologies facilitate personalized treatment plans and improve the accuracy and speed of medical diagnostics, contributing significantly to the elevation of patient care standards and a sustainable, resilient healthcare infrastructure in line with the objectives of the Health Sector Transformation Program.

KFSH&RC continues to push the boundaries of medical research addressing pressing health challenges and contributing to Saudi Arabia’s public health landscape, with discoveries like the PfAP2-MRP gene crucial for malaria treatment and the identification of the new Riyadhensis bacteria strain. These discoveries have not only improved diagnostic accuracy but also facilitated early interventions, ensuring timely and effective patient support, in line with the national objectives to reduce chronic disease prevalence.

These comprehensive efforts are supported by KFSH&RC’s robust educational initiatives, which prepare the next generation of medical professionals through training programs and international collaborations.

Recognized by ‘Brand Finance’ in 2024 as the most valuable healthcare brand in Saudi Arabia and the Middle East for the second consecutive year, placing 9th in Saudi Arabia and 28th in the Middle East. Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country’s top ten most valuable brands.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/003e76ab-3d93-42d4-9edf-5e652a14c559

Copyright © 2024 GlobeNewswire, Inc.

GlobeNewswire Distribution ID 9114722

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest

Curia & Carterra Biologics Symposium

Biologics symposium slated for May 31 in Seattle, WA

ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization and Carterra Inc., the world leader in label-free high throughput antibody and small molecule drug discovery, today announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott in Seattle, Washington.

The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada. The symposium will bring together all levels of scientific leadership from the biotech and pharma communities.

“We are thrilled to be partnering with Carterra to organize this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery,” said Steve Lavezoli, Vice President of Biologics at Curia. “We are also looking forward to sharing our optimal, high-quality and accelerated antibody discovery workflows to first-to-human antibody discovery, development and clinical manufacturing. Antibodies discovered and/or engineered with Curia’s platform technology are in the clinic and we have over 230 successful antibody discovery campaigns performed for the biotech community.”

Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics. The symposium will highlight Curia’s technology platform and integrated services with a focus on the development of enhanced mouse systems for antibody generation and high-throughput single B cell screening. The combination of next generation sequencing (NGS) and rapid recombinant production of milligram to gram quantities of purified monoclonal antibody (mAb) significantly accelerates identification of development candidate leads.

Since 2017, Carterra has been selling its powerful LSA® high-throughput biosensor to analyze and characterize antibodies using Surface Plasmon Resonance (SPR). With the launch of its LSAXT platform last year, Carterra now offers products that can perform small molecule analysis as well as antibody discovery. The LSA platform has been profiled in several peer-reviewed papers in Science, Nature and Cell, detailing the path of multiple therapeutics entering clinical trials. At the symposium, several leading scientists in biopharma will be sharing their insights into their specific areas of drug discovery and will highlight the transformative impact of integrating HT-SPR technology, AI/ML and other new technologies.

“We are excited to be partnering with Curia on our symposium. Carterra symposia are scientific events that we host each year throughout the U.S. and Europe,” stated Chris M. Silva, Vice President of Marketing and Product at Carterra. “These symposia help us to share the latest technology advancements and important data generated from the workflows of scientists using Carterra’s label-free platforms. Coming to the Pacific Northwest is an opportunity to create a deeper understanding of the technology in pharma and biotechs in this region.”

Click here to RSVP for the event. Registration is required as seating is limited.

About Curia:
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offerings span discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

About Carterra, Inc.:
Carterra, Inc. is a privately held company. Its HT-SPR technology provides large-molecule and small-molecule drug discovery customers with screening and characterization throughput and functionality that scales with omics-level applications, condensing months of work down to days. Our solutions have enabled multiple therapeutics and breakthrough research and helped academic and translational researchers and biopharmaceutical companies in oncology, immunology, neuroscience, and more.  Carterra is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. To learn more, visit www.carterra-bio.com or connect with us on LinkedIn or X (Twitter).

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Carterra Media Contact:
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9114095

Hitachi Energy supports long-term operation of largest HVDC-connected wind energy project in U.S.

Multi-year agreement provides service solutions to the SunZia Transmission Project, linking New Mexico’s wind farms to Arizona’s grid, increasing renewable energy to Western States

Zurich, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) — Hitachi Energy announced that it has signed a multi-year agreement with Pattern Energy to support its high-voltage direct current (HVDC) technologies for the SunZia Transmission Project. The link will connect the 3,515-megawatt (MW) SunZia Wind project in New Mexico to Arizona and Western states, which will be one of the world’s largest transmission links delivering renewable energy.

The long-term agreement will provide service solutions for the SunZia Transmission HVDC link, currently under construction1, owned by Pattern Energy, one of the world’s largest privately-owned developers and operators of renewable energy and transmission projects. Hitachi Energy’s HVDC Light® technology will efficiently transfer and integrate huge volumes of wind power over more than 885 kilometers (550 miles) into the regional power grid. This will significantly increase the availability of sustainable energy for homes and businesses throughout the region when it enters operation, which is expected in 2025.

EnCompass™ is Hitachi Energy’s portfolio of partnership-oriented service offerings, signaling a step-change in life cycle thinking. This order underlines Hitachi Energy’s commitment to trusted long-term partnerships and builds on its proven track record of delivering innovative and reliable energy service solutions 2.

When complete, SunZia Wind will have a total power capacity of 3,515 MW, enough clean, renewable electricity to provide power to approximately three million Americans3. The HVDC link will efficiently transmit up to 3,000 MW of this power west to Arizona. The HVDC Light system will be the largest voltage source converter (VSC) installation in the United States, one of the largest worldwide, and one of the country’s longest HVDC connections.

“We’re proud to be selected once again to provide our unique service expertise to keep the important SunZia link operating at maximum efficiency, performance, and reliability,” said Andreas Berthou, global head of the HVDC business at Hitachi Energy. “With our service solutions, we are building a partnership ecosystem to ensure continued support to the HVDC link throughout its lifetime, delivering cutting edge digital service with sustainability and customer-value at its core.”

“The SunZia transmission and Wind projects provide a roadmap to accelerate the transition to renewable energy,” said Paul Haberlein, VP of Operational Excellence at Pattern Energy. “SunZia will play a vital role in delivering clean and sustainable energy to Western states. Pattern selected Hitachi Energy, a global technology leader, as our partner to engineer, manufacture and maintain the HVDC converter stations after they enter operation.”

Service for an HVDC system includes a wide range of activities and support, including scheduled maintenance, cyber services, on-site engineering support and life cycle assessment of the HVDC Light stations.

Hitachi Energy recognizes that the energy transition begins with existing infrastructure and the company is championing the urgency and the pace of change needed to reach Net Zero.  Leveraging on the company’s century of experience and expertise, its dedicated teams deliver exceptional service solutions that cover the entire life cycle of their customer’s assets, ensuring resilient operations. The company offers expert advice at every stage of the process across the whole portfolio, addressing both present and future needs to help customers achieve a sustainable energy future.

Hitachi Energy pioneered commercial HVDC technology 70 years ago and has delivered more than half of the world’s HVDC projects and has the largest installed base of HVDC in the world.

Notes to editors

https://www.hitachienergy.com/se/sv/about-us/customer-success-stories/sunzia
https://www.hitachienergy.com/services-and-consulting/services/encompass-agreements
https://sunzia.net/impact/

About Hitachi Energy 
Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We are advancing the world’s energy system to be more sustainable, flexible and secure and we collaborate with customers and partners to enable a sustainable energy future – for today’s generations and those to come. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries, serving customers in utility, industry, transportation, data centers and infrastructure sectors. With innovative technologies and services including the integration of more than 150 gigawatts of HVDC links into the power system, we help make the energy value chain more efficient, making electricity more accessible to all. Together with stakeholders across sectors and geographies, we enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. Headquartered in Switzerland, we employ around 45,000 people in 90 countries and generate business volumes of around $13 billion USD.

https://www.hitachienergy.com
https://www.linkedin.com/company/hitachienergy
https://twitter.com/HitachiEnergy

About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachment

Kurt Steinert
Hitachi Energy North America
rebecca.bleasdale@hitachienergy.com

Global Media Relations
Hitachi Energy
media.relations@hitachienergy.com

GlobeNewswire Distribution ID 9112623